Published in Med J Aust on April 03, 1989
Convulsions and transient cortical blindness after cisplatin. BMJ (1991) 0.84
Electron microscopy in rat brain slices reveals rapid accumulation of Cisplatin on ribosomes and other cellular components only in glia. Chemother Res Pract (2014) 0.75
Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Med J (2015) 0.75
Effects of intensity-modulated radiotherapy and chemoradiotherapy on attention in patients with nasopharyngeal cancer. Oncotarget (2017) 0.75
Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model. BMC Complement Altern Med (2017) 0.75
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1992) 2.90
Localised prostate cancer: which way forward? Med J Aust (1995) 2.04
The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol (1993) 1.79
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 1.73
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer (1993) 1.64
Targeting BRAF for patients with melanoma. Br J Cancer (2010) 1.56
Sequence and evolution of the human T-cell antigen receptor beta-chain genes. Proc Natl Acad Sci U S A (1985) 1.50
Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy. Lancet (1989) 1.47
Pulmonary toxicity associated with bleomycin. Med J Aust (1994) 1.39
Health-care interpreters and cancer. Med J Aust (1989) 1.39
Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus. Oncogene (1992) 1.20
Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours. Support Care Cancer (2012) 0.97
Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol (1987) 0.97
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. Clin Endocrinol (Oxf) (1985) 0.95
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer (2009) 0.95
Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer. Br J Cancer (1985) 0.95
Extraskeletal Ewing's sarcoma: a clinical, morphological and ultrastructural analysis of five cases with a review of the literature. Eur J Cancer Clin Oncol (1986) 0.95
A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol (1989) 0.93
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Br J Cancer (1985) 0.93
Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet (1984) 0.91
Chemotherapy of endodermal sinus tumour (yolk sac tumour) of the ovary: preliminary communication. J R Soc Med (1982) 0.89
Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort. Breast (2010) 0.88
Cardiotoxicity associated with mitoxantrone. Lancet (1984) 0.87
Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer. Br Med J (Clin Res Ed) (1983) 0.87
Tetany associated with cis-platin. Lancet (1980) 0.84
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. Invest New Drugs (1985) 0.84
Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01. Gynecol Oncol (2006) 0.83
Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer (2007) 0.82
A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. Eur J Cancer Clin Oncol (1988) 0.81
Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rev (1983) 0.80
High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev (1983) 0.80
The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust (1988) 0.79
Identifying priorities of psychosocial need in cancer patients. Br J Cancer (1990) 0.78
Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer. Br J Cancer (1985) 0.78
Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol (2014) 0.77
Isolated central nervous system relapse of non-seminomatous germ cell tumour of the testis. A case report and review of the literature. Oncology (2001) 0.77
Docetaxel-induced myositis: report of a novel side-effect. Intern Med J (2005) 0.77
Biliary elimination of cyclophosphamide in man. Cancer Chemother Pharmacol (1982) 0.77
Role of aminoglutethimide in male breast cancer. Br J Cancer (1986) 0.77
Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy. Postgrad Med J (1983) 0.77
Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin. Aust N Z J Med (1998) 0.76
Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep (1986) 0.76
Paraneoplastic myelopathy at diagnosis in a patient with pathologic stage 1A Hodgkin disease. Cancer (1992) 0.76
Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer. Thorax (1985) 0.75
Doctors, nuclear war, and a town like Alice. Med War (1986) 0.75
Chemotherapeutic induced fascial oedema. Ann Rheum Dis (2005) 0.75
Epirubicin: a phase II study in recurrent small-cell lung cancer. Cancer Chemother Pharmacol (1991) 0.75
Low-dose aminoglutethimide and aromatase inhibition. Lancet (1985) 0.75
The use of L-dopa and carbidopa in metastatic malignant melanoma. J Invest Dermatol (1991) 0.75
Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: an overview. Eur J Cancer Clin Oncol (1989) 0.75
Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol (2013) 0.75
A phase II trial of oral 4'demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer. Invest New Drugs (1988) 0.75
Cytarabine: an inactive drug for extensive-stage small cell lung cancer. Cancer Treat Rep (1986) 0.75
Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. Eur J Cancer (1995) 0.75
A phase II study of carboplatin and cisplatin in advanced ovarian cancer. Eur J Gynaecol Oncol (1994) 0.75
Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer. Cancer Chemother Pharmacol (1990) 0.75
The treatment of disseminated prostate cancer with estramustine. Aust N Z J Surg (1992) 0.75
Cancer in the family: risks and management. Med J Aust (2000) 0.75
Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix. Gynecol Oncol (1992) 0.75
A novel model for metastasis suppression involving regulation of nuclear precursor messenger-RNA stability. Int J Oncol (1995) 0.75
Carboplatin-containing regimens for small cell lung cancer: implications for management in the elderly. Semin Oncol (1992) 0.75
Bone metastases in hypernephroma. Frequency of scapular involvement. Cancer (1989) 0.75
Non-coexpression of collagenase and transin in malignant epithelial cells. Int J Oncol (1997) 0.75